PMC:7408073 / 83891-84201 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2879","span":{"begin":287,"end":291},"obj":"Gene"},{"id":"2894","span":{"begin":106,"end":114},"obj":"Species"},{"id":"2895","span":{"begin":197,"end":207},"obj":"Species"},{"id":"2896","span":{"begin":208,"end":216},"obj":"Species"},{"id":"2905","span":{"begin":5,"end":17},"obj":"Disease"},{"id":"2906","span":{"begin":19,"end":30},"obj":"Disease"},{"id":"2907","span":{"begin":38,"end":49},"obj":"Disease"},{"id":"2908","span":{"begin":60,"end":68},"obj":"Disease"},{"id":"2909","span":{"begin":73,"end":96},"obj":"Disease"},{"id":"2910","span":{"begin":120,"end":132},"obj":"Disease"},{"id":"2911","span":{"begin":156,"end":168},"obj":"Disease"},{"id":"2912","span":{"begin":186,"end":193},"obj":"Disease"}],"attributes":[{"id":"A2879","pred":"tao:has_database_id","subj":"2879","obj":"Gene:59272"},{"id":"A2894","pred":"tao:has_database_id","subj":"2894","obj":"Tax:9606"},{"id":"A2895","pred":"tao:has_database_id","subj":"2895","obj":"Tax:2697049"},{"id":"A2896","pred":"tao:has_database_id","subj":"2896","obj":"Tax:9606"},{"id":"A2906","pred":"tao:has_database_id","subj":"2906","obj":"MESH:D013610"},{"id":"A2907","pred":"tao:has_database_id","subj":"2907","obj":"MESH:D007022"},{"id":"A2908","pred":"tao:has_database_id","subj":"2908","obj":"MESH:C000657245"},{"id":"A2909","pred":"tao:has_database_id","subj":"2909","obj":"MESH:D000860"},{"id":"A2910","pred":"tao:has_database_id","subj":"2910","obj":"MESH:D006973"},{"id":"A2911","pred":"tao:has_database_id","subj":"2911","obj":"MESH:D006973"},{"id":"A2912","pred":"tao:has_database_id","subj":"2912","obj":"MESH:D000860"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulati"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T484","span":{"begin":38,"end":49},"obj":"Disease"},{"id":"T485","span":{"begin":60,"end":68},"obj":"Disease"},{"id":"T486","span":{"begin":197,"end":205},"obj":"Disease"},{"id":"T487","span":{"begin":197,"end":201},"obj":"Disease"}],"attributes":[{"id":"A484","pred":"mondo_id","subj":"T484","obj":"http://purl.obolibrary.org/obo/MONDO_0005468"},{"id":"A485","pred":"mondo_id","subj":"T485","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A486","pred":"mondo_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A487","pred":"mondo_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulati"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T71125","span":{"begin":94,"end":96},"obj":"Chemical"}],"attributes":[{"id":"A26558","pred":"chebi_id","subj":"T71125","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulati"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T145","span":{"begin":19,"end":30},"obj":"Phenotype"},{"id":"T146","span":{"begin":38,"end":49},"obj":"Phenotype"},{"id":"T147","span":{"begin":73,"end":80},"obj":"Phenotype"},{"id":"T148","span":{"begin":186,"end":193},"obj":"Phenotype"}],"attributes":[{"id":"A145","pred":"hp_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/HP_0001649"},{"id":"A146","pred":"hp_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/HP_0002615"},{"id":"A147","pred":"hp_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/HP_0012418"},{"id":"A148","pred":"hp_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/HP_0012418"}],"text":"10), eosinopaenia, tachycardia, normo/hypotension (although COVID-19 and hypoxia increase Ang II and many patients are “hypertensive” and/or receiving anti-hypertensive medications) and hypoxia in SARS-CoV-2 patients are compatible with downstream events stemming from both an excessive ACE2 pathway upregulati"}